Portfolio Holdings Detail for ISIN IE00B8FHGS14

Stock Name / Fund	iShares Edge MSCI World Minimum Volatility UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares VI Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300VML6THE3JJOS76
ETF Ticker	MINV(GBX) LSE
ETF Ticker	IQQ0(EUR) F
ETF Ticker	MINV.LS(GBX) CXE
ETF Ticker	MVOL.LS(USD) CXE
ETF Ticker	MVOL.MI(EUR) CXE
ETF Ticker	MVOLz(CHF) CXE
ETF Ticker	MVOL(EUR) ETF Plus
ETF Ticker	MINV.L(GBP) LSE

Holdings detail for BMRN

Show aggregate BMRN holdings

News associated with BMRN

BioMarin Pharmaceutical (NASDAQ:BMRN) Coverage Initiated at HC Wainwright

HC Wainwright assumed coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) in a note issued to investors on Monday, MarketBeat.com reports. The firm set a “neutral” rating and a $60.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 7.74% from the stock’s previous […] - 2025-09-10 03:13:10

Predicting the Next Rule Breaker Buyout

In this Motley Fool Money podcast, Motley Fool analyst Karl Thiel and contributors Rick Munarriz and Jason Hall dig into four growth stocks ripe for the acquiring. There's also two sides to Tesla's changing AI story and a new kind of stock quote game. - 2025-08-19 01:08:00

9,709 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Bought by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. bought a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 9,709 shares of the biotechnology company’s stock, valued at approximately $686,000. Several other hedge funds and other institutional investors also […] - 2025-08-13 04:49:08

Natixis Advisors LLC Grows Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Natixis Advisors LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 68.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,226 shares of the biotechnology company’s stock after buying an additional 13,488 shares during the quarter. Natixis Advisors […] - 2025-08-08 07:20:44

Guggenheim Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its target price hoisted by investment analysts at Guggenheim from $101.00 to $106.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price objective indicates a potential upside of 78.27% from the company’s current […] - 2025-08-08 04:26:58

BMRN Makes Bullish Cross Above Critical Moving Average

In trading on Tuesday, shares of BioMarin Pharmaceutical Inc (Symbol: BMRN) crossed above their 200 day moving average of $63.38, changing hands as high as $63.97 per share. BioMarin Pharmaceutical Inc shares are currently trading up about 5.7% on the day. The chart below show - 2025-08-05 12:47:37

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $93.74 Average Target Price from Analysts

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-four research firms that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and eighteen have given a buy recommendation to the company. […] - 2025-08-05 02:55:15

Biomarin Pharmaceutical Q2 25 Earnings Conference Call At 4:30 PM ET

(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) will host a conference call at 4:30 PM ET on August 4, 2025, to discuss Q2 25 earnings results. - 2025-08-04 08:30:49

Signaturefd LLC Increases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Signaturefd LLC boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 19.1% during the 1st quarter, Holdings Channel reports. The institutional investor owned 2,191 shares of the biotechnology company’s stock after acquiring an additional 352 shares during the period. Signaturefd LLC’s holdings in BioMarin Pharmaceutical were worth $155,000 as of […] - 2025-07-21 05:36:50

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 5.0% in the first quarter, Holdings Channel reports. The firm owned 4,572 shares of the biotechnology company’s stock after buying an additional 217 shares during the period. Nisa Investment Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $323,000 as […] - 2025-07-17 06:25:00

Cerity Partners LLC Raises Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Cerity Partners LLC raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 203.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 84,832 shares of the biotechnology company’s stock after acquiring an additional 56,897 shares during the period. […] - 2025-07-17 05:51:03

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $113.00

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective upped by JPMorgan Chase & Co. from $108.00 to $113.00 in a research report sent to investors on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock. Other equities analysts have also issued research reports about the […] - 2025-07-17 04:48:52

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Xponance Inc.

Xponance Inc. raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.6% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 31,877 shares of the biotechnology company’s stock after buying an additional 202 shares during the quarter. Xponance Inc.’s holdings in BioMarin Pharmaceutical were worth […] - 2025-07-15 07:02:50

D.A. Davidson & CO. Has $480,000 Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

D.A. Davidson & CO. lessened its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 9.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,788 shares of the biotechnology company’s stock after selling 746 shares during the quarter. D.A. Davidson […] - 2025-07-11 05:32:53

Brokerages Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) PT at $93.61

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The average 1 […] - 2025-07-11 02:56:50

Principal Financial Group Inc. Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Principal Financial Group Inc. lifted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 455,485 shares of the biotechnology company’s stock after purchasing an additional 1,549 shares during […] - 2025-07-08 06:26:49

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.6% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 467,245 shares of the biotechnology company’s stock after selling 2,798 shares during the period. Sumitomo Mitsui Trust Group […] - 2025-07-03 06:13:02

Bessemer Group Inc. Has $327,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Bessemer Group Inc. reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 12.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,618 shares of the biotechnology company’s stock after selling 683 shares during the quarter. Bessemer Group Inc.’s […] - 2025-07-03 05:00:50

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 12.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 97,261 shares of the biotechnology company’s stock after purchasing an additional 10,687 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in BioMarin Pharmaceutical were […] - 2025-06-30 05:06:50

Kentucky Retirement Systems Insurance Trust Fund Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 5,490 shares of the biotechnology company’s stock, valued at approximately $388,000. A number of other institutional investors have also […] - 2025-06-26 05:04:54

Kentucky Retirement Systems Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Kentucky Retirement Systems bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 12,890 shares of the biotechnology company’s stock, valued at approximately $911,000. Other hedge funds have also recently added to or reduced their stakes in the company. Farther Finance […] - 2025-06-25 05:40:49

Exchange Traded Concepts LLC Acquires 979 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Exchange Traded Concepts LLC boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 5.2% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,796 shares of the biotechnology company’s stock after acquiring an additional 979 shares during the quarter. Exchange Traded […] - 2025-06-19 04:58:54

Mn Services Vermogensbeheer B.V. Boosts Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Mn Services Vermogensbeheer B.V. increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 12.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 35,500 shares of the biotechnology company’s stock after buying an additional 3,800 shares during the period. Mn Services Vermogensbeheer […] - 2025-06-18 05:44:54

NorthCrest Asset Manangement LLC Acquires Shares of 4,885 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

NorthCrest Asset Manangement LLC acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,885 shares of the biotechnology company’s stock, valued at approximately $345,000. Other hedge funds and […] - 2025-06-16 05:36:54

UMB Bank n.a. Increases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

UMB Bank n.a. grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 120.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,247 shares of the biotechnology company’s stock after acquiring an additional 1,228 shares during the period. UMB Bank […] - 2025-06-12 05:32:57

Gateway Investment Advisers LLC Cuts Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Gateway Investment Advisers LLC lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 22.2% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,512 shares of the biotechnology company’s stock after selling 1,003 shares during the period. Gateway Investment Advisers LLC’s […] - 2025-06-10 05:26:59

Here Are All 6 Stocks I've Bought Through 5 Months of 2025

It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high. But over the next two months, tariff-related unce - 2025-06-05 04:06:00

Tidal Investments LLC Sells 17,428 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Tidal Investments LLC lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 57.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,039 shares of the biotechnology company’s stock after selling 17,428 shares during the quarter. Tidal Investments LLC’s holdings in BioMarin […] - 2025-05-27 05:21:04

Quantinno Capital Management LP Purchases Shares of 5,848 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Quantinno Capital Management LP bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,848 shares of the biotechnology company’s stock, valued at approximately $384,000. A number […] - 2025-05-26 04:58:58

Analysts See 10% Upside For The Holdings of ILCB

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-19 07:58:34

iShares Edge MSCI World Minimum Volatility UCITS ETF USD (Acc) BMRN holdings

Share Trades of BMRN by Blackrock for IE00B8FHGS14

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-17	BUY	251	55.240	54.000	54.124	USD 13,585	60.90
2025-11-14	SELL	-502	55.295	53.670	53.832	USD -27,024	60.92 Profit of 3,560 on sale
2025-11-04	SELL	-530	52.760	51.800	51.896	USD -27,505	61.18 Profit of 4,919 on sale
2025-10-31	BUY	251	53.620	51.020	51.280	USD 12,871	61.24
2025-10-28	SELL	-504	53.490	56.800	56.469	USD -28,460	61.35 Profit of 2,462 on sale
2025-10-21	SELL	-500	53.810	53.980	53.963	USD -26,981	61.52 Profit of 3,776 on sale
2025-10-14	SELL	-251	52.470	52.810	52.776	USD -13,247	61.70 Profit of 2,240 on sale
2025-10-08	SELL	-996	54.690	55.200	55.149	USD -54,928	61.77 Profit of 6,598 on sale
2025-10-07	SELL	-5,880	54.700	56.260	56.104	USD -329,892	61.80 Profit of 33,519 on sale
2025-10-02	SELL	-996	55.570	55.990	55.948	USD -55,724	61.89 Profit of 5,917 on sale
2025-09-25	SELL	-250	52.620	54.500	54.312	USD -13,578	62.07 Profit of 1,940 on sale
2025-09-24	SELL	-1,100	53.770	53.870	53.860	USD -59,246	62.11 Profit of 9,075 on sale
2025-09-16	BUY	227	53.940	54.420	54.372	USD 12,342	62.22
2025-09-12	SELL	-988	54.090	56.070	55.872	USD -55,202	62.30 Profit of 6,349 on sale
2025-09-09	SELL	-542	55.690	56.500	56.419	USD -30,579	62.40 Profit of 3,241 on sale
2025-09-02	BUY	249	59.090	59.240	59.225	USD 14,747	62.49
2025-08-27	BUY	246	58.660	58.800	58.786	USD 14,461	62.56
2025-08-26	SELL	-40,531	57.450	58.730	58.602	USD -2,375,198	62.58 Profit of 161,339 on sale
2025-08-13	SELL	-816	58.300	58.620	58.588	USD -47,808	62.78 Profit of 3,418 on sale
2025-08-12	SELL	-419	56.860	57.460	57.400	USD -24,051	62.81 Profit of 2,266 on sale
2025-08-04	SELL	-2,430	60.310	60.630	60.598	USD -147,253	62.92 Profit of 5,635 on sale
2025-07-28	SELL	-428	58.140	59.400	59.274	USD -25,369	63.05 Profit of 1,615 on sale
2025-07-23	SELL	-1,217	59.670	60.430	60.354	USD -73,451	63.11 Profit of 3,350 on sale
2025-07-22	SELL	-1,584	59.200	59.220	59.218	USD -93,801	63.13 Profit of 6,194 on sale
2025-07-21	SELL	-792	56.560	57.550	57.451	USD -45,501	63.17 Profit of 4,526 on sale
2025-07-15	SELL	-1,576	56.620	58.670	58.465	USD -92,141	63.29 Profit of 7,610 on sale
2025-07-11	SELL	-788	58.100	58.500	58.460	USD -46,066	63.35 Profit of 3,856 on sale
2025-07-02	BUY	394	57.170	57.610	57.566	USD 22,681	63.58
2025-06-30	SELL	-1,194	54.970	55.960	55.861	USD -66,698	63.64 Profit of 9,284 on sale
2025-06-27	SELL	-1,326	55.170	55.200	55.197	USD -73,191	63.69 Profit of 11,261 on sale
2025-06-26	BUY	396	54.100	54.550	54.505	USD 21,584	63.75
2025-06-25	SELL	-398	54.140	54.610	54.563	USD -21,716	63.81 Profit of 3,680 on sale
2025-06-23	SELL	-1,206	54.080	56.000	55.808	USD -67,304	63.93 Profit of 9,795 on sale
2025-06-20	SELL	-403	55.000	56.250	56.125	USD -22,618	63.99 Profit of 3,168 on sale
2025-06-16	SELL	-4,072	56.240	56.510	56.483	USD -229,999	64.21 Profit of 31,473 on sale
2025-06-13	SELL	-397	56.220	57.360	57.246	USD -22,727	64.27 Profit of 2,787 on sale
2025-06-12	SELL	-794	57.280	57.650	57.613	USD -45,745	64.31 Profit of 5,319 on sale
2025-06-11	SELL	-1,985	57.160	57.990	57.907	USD -114,945	64.36 Profit of 12,809 on sale
2025-06-09	SELL	-397	56.880	57.460	57.402	USD -22,789	64.46 Profit of 2,801 on sale
2025-05-30	SELL	-393	58.070	58.480	58.439	USD -22,967	64.79 Profit of 2,496 on sale
2025-05-28	SELL	-391	58.090	59.120	59.017	USD -23,076	64.88 Profit of 2,293 on sale
2025-05-21	SELL	-391	58.480	59.510	59.407	USD -23,228	65.14 Profit of 2,242 on sale
2025-05-14	SELL	-5,122	58.700	60.030	59.897	USD -306,792	65.37 Profit of 28,058 on sale
2025-05-09	BUY	2,015	58.860	60.660	60.480	USD 121,867	65.50
2025-05-07	SELL	-1,556	59.320	60.160	60.076	USD -93,478	65.60 Profit of 8,593 on sale
2025-05-01	BUY	389	62.710	63.620	63.529	USD 24,713	65.73
2025-04-29	SELL	-4,246	63.280	64.080	64.000	USD -271,744	65.77 Profit of 7,514 on sale
2025-04-28	BUY	5,201	62.980	63.870	63.781	USD 331,725	65.79
2025-04-25	BUY	374	63.300	63.440	63.426	USD 23,721	65.81
2025-04-23	BUY	1,245	61.940	63.390	63.245	USD 78,740	65.88
2025-04-22	BUY	3,384	61.500	61.530	61.527	USD 208,207	65.91
2025-04-15	SELL	-1,128	60.020	60.930	60.839	USD -68,626	66.23 Profit of 6,078 on sale
2025-04-14	BUY	2,014	59.670	59.990	59.958	USD 120,755	66.29
2025-04-11	BUY	1,900	56.820	57.000	56.982	USD 108,266	66.38
2025-04-09	SELL	-1,122	59.430	59.880	59.835	USD -67,135	66.54 Profit of 7,524 on sale
2025-04-08	SELL	-1,496	55.890	61.070	60.552	USD -90,586	66.64 Profit of 9,114 on sale
2025-04-07	SELL	-374	59.160	60.610	60.465	USD -22,614	66.72 Profit of 2,339 on sale
2025-04-04	BUY	376	60.260	66.490	65.867	USD 24,766	66.78
2025-04-01	BUY	1,500	67.940	70.630	70.361	USD 105,541	66.75
2025-03-27	SELL	-754	72.830	73.180	73.145	USD -55,151	66.60 Loss of -4,934 on sale
2025-03-21	SELL	-376	71.240	72.060	71.978	USD -27,064	66.39 Loss of -2,103 on sale
2025-03-14	BUY	1,134	69.440	70.410	70.313	USD 79,735	66.12
2025-03-13	BUY	378	70.600	71.930	71.797	USD 27,139	66.06
2025-03-12	BUY	756	70.540	70.820	70.792	USD 53,519	66.01
2025-03-11	BUY	756	70.490	72.350	72.164	USD 54,556	65.96
2025-03-10	SELL	-377	72.030	72.990	72.894	USD -27,481	65.88 Loss of -2,643 on sale
2025-03-07	BUY	6,426	72.230	73.510	73.382	USD 471,553	65.81
2025-03-05	BUY	1,880	71.190	71.470	71.442	USD 134,311	65.74
2025-03-04	BUY	752	70.510	71.580	71.473	USD 53,748	65.68
2025-03-03	BUY	1,504	71.020	71.700	71.632	USD 107,735	65.61
2025-02-27	BUY	376	69.120	70.070	69.975	USD 26,311	65.50
2025-02-26	BUY	2,992	68.810	71.300	71.051	USD 212,585	65.45
2025-02-25	BUY	746	71.170	71.580	71.539	USD 53,368	65.38
2025-02-20	BUY	1,122	68.730	70.500	70.323	USD 78,902	65.24
2025-02-05	BUY	371	64.190	64.530	64.496	USD 23,928	65.37
2025-02-04	BUY	371	62.870	63.530	63.464	USD 23,545	65.41
2025-01-31	SELL	-372	63.360	64.330	64.233	USD -23,895	65.49 Profit of 469 on sale
2025-01-30	BUY	372	63.880	64.230	64.195	USD 23,881	65.52
2025-01-29	SELL	-371	63.460	64.050	63.991	USD -23,741	65.56 Profit of 581 on sale
2025-01-28	BUY	744	63.250	63.480	63.457	USD 47,212	65.60
2025-01-27	SELL	-372	61.800	63.150	63.015	USD -23,442	65.67 Profit of 988 on sale
2025-01-10	BUY	5,250	67.380	67.940	67.884	USD 356,391	66.36
2025-01-08	BUY	3,772	68.380	69.700	69.568	USD 262,410	66.27
2024-12-18	SELL	-758	64.690	67.580	67.291	USD -51,007	66.37 Loss of -695 on sale
2024-12-10	SELL	-379	66.430	67.070	67.006	USD -25,395	66.37 Loss of -240 on sale
2024-12-03	SELL	-758	63.190	65.130	64.936	USD -49,221	66.46 Profit of 1,155 on sale
2024-11-29	SELL	-379	66.030	66.170	66.156	USD -25,073	66.53 Profit of 142 on sale
2024-11-22	SELL	-1,137	64.260	64.460	64.440	USD -73,268	66.89 Profit of 2,788 on sale
2024-11-05	SELL	-3,024	66.040	66.230	66.211	USD -200,222	68.74 Profit of 7,645 on sale
2024-10-29	BUY	377	69.910	70.560	70.495	USD 26,577	70.17
2024-10-24	BUY	377	70.390	70.980	70.921	USD 26,737	70.26

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of BMRN

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy